Carisbamate

Carisbamate

Gene therapy
Clinical data
Physiological data
Legal status
Pharmacokinetic data
Identifiers
IUPAC name [(2R)-2-(2-Chlorophenyl)-2-hydroxy-ethyl] carbamate
PubChem Template:Abbreviation	6918474
Chemical and physical data
Formula	C9H10ClNO3
Molar mass	215.633 g/mol

WikiDoc Resources for Carisbamate
Articles
Most recent articles on Carisbamate Most cited articles on Carisbamate Review articles on Carisbamate Articles on Carisbamate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Carisbamate Images of Carisbamate Photos of Carisbamate Podcasts & MP3s on Carisbamate Videos on Carisbamate
Evidence Based Medicine
Cochrane Collaboration on Carisbamate Bandolier on Carisbamate TRIP on Carisbamate
Clinical Trials
Ongoing Trials on Carisbamate at Clinical Trials.gov Trial results on Carisbamate Clinical Trials on Carisbamate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Carisbamate NICE Guidance on Carisbamate NHS PRODIGY Guidance FDA on Carisbamate CDC on Carisbamate
Books
Books on Carisbamate
News
Carisbamate in the news Be alerted to news on Carisbamate News trends on Carisbamate
Commentary
Blogs on Carisbamate
Definitions
Definitions of Carisbamate
Patient Resources / Community
Patient resources on Carisbamate Discussion groups on Carisbamate Patient Handouts on Carisbamate Directions to Hospitals Treating Carisbamate Risk calculators and risk factors for Carisbamate
Healthcare Provider Resources
Symptoms of Carisbamate Causes & Risk Factors for Carisbamate Diagnostic studies for Carisbamate Treatment of Carisbamate
Continuing Medical Education (CME)
CME Programs on Carisbamate
International
Carisbamate en Espanol Carisbamate en Francais
Business
Carisbamate in the Marketplace Patents on Carisbamate
Experimental / Informatics
List of terms related to Carisbamate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Carisbamate (YKP 509) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Pharma (currently SK Holding), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partical seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase 3 clinical trial for the treatment of partial seizures. As of September, 2007, the trial had completed enrollment, but the blind had not been broken. Assuming the the phase III trial demonstrates positive results consistent with the phase II study, the company expects to file for registration in 2008. Its mechanism of action is unknown .